
Share
For decades, families watching type 3 Gaucher disease steal a child's memory and movement had no targeted options. Sanofi's newly approved Infilbray is the first drug built to reach the brain itself.
Imagine a disease that slowly takes away your ability to think clearly, to walk steadily, to control your own muscles, while doctors have medicine for everything else your body is going through except that. That has been the reality for families living with type 3 Gaucher disease. This week, that reality changed.
The FDA approved Infilbray, a Sanofi drug known during development as venglustat, as the first therapy specifically cleared to treat the neurological symptoms of Gaucher disease type 3. The decision, announced Wednesday, covers adults and children weighing at least 15 kilograms, or about 33 pounds. It is a narrow approval in terms of who qualifies. It is an enormous one in terms of what it represents.
Gaucher disease is rare and genetic. Mutations in the GBA1 gene cause a shortage of an enzyme called glucocerebrosidase. Think of that enzyme as a cleanup crew whose job is to break down fatty molecules called glycosphingolipids. Without enough of it, those fatty molecules pile up inside organs, like garbage accumulating when trash pickup stops. In type 1 Gaucher, that buildup mostly affects the liver, spleen, and bones. Type 3 is crueler. The fatty accumulation reaches the central nervous system, driving dementia and loss of muscle control on top of the organ enlargement patients already contend with.
Existing enzyme replacement therapies could manage the systemic damage, the liver and spleen problems, but they could not touch the brain. The reason comes down to basic biology: the blood-brain barrier, a protective filter that keeps large molecules out of the brain, blocks those injected enzymes just as effectively as it blocks harmful substances. Infilbray gets around that wall. It is a small molecule, and small molecules can cross where larger drugs cannot. Rather than replacing the missing enzyme, it works upstream, blocking the enzyme responsible for making glycosphingolipids in the first place, so there is less fatty material to accumulate anywhere, brain included.
The approval rests on a Phase 3 trial that enrolled adults and children age 12 and older with type 3 Gaucher disease. Every participant had already reached systemic disease stabilization through prior enzyme replacement therapy, meaning their liver and spleen symptoms were under control but their neurological decline was not.
Researchers compared a daily oral dose of the study drug against intravenous enzyme replacement therapy given every two weeks. After one year, Infilbray showed a statistically significant improvement on a composite test that assessed multiple neurological measures at once, capturing the kind of cognitive and motor ground that older treatments simply could not reach.
That success came with tradeoffs worth naming plainly. The most common side effects in the trial were diarrhea, an enlarged spleen, and nausea, manageable symptoms for most patients but not trivial ones. More seriously, the Infilbray label carries a warning that the drug may increase the risk of suicidal thoughts and behavior. Anyone starting this treatment, along with their families and care teams, will need to watch for mood changes closely. A drug that reaches the brain to fix one problem can, unfortunately, touch other parts of brain chemistry too.

Dr. Pramod Mistry, director of the Yale Lysosomal Disease Center and Gaucher Disease Treatment Center, captured the significance in Sanofi's approval announcement. "We have been able to treat the systemic manifestations of type 3 Gaucher disease, while the neurological manifestations remained beyond the reach of available therapies," he said. "The availability of a medicine capable of addressing the neurological manifestations of this devastating disorder represents a major milestone for patients, families, and the global type 3 Gaucher disease community."
Sanofi is not new to this disease. The company already sells Cerezyme, an enzyme replacement therapy that competes with similar products from Takeda Pharmaceutical and Pfizer, all three approved for type 1 Gaucher. Earlier this year, Cerezyme's label expanded to cover the non-neurological symptoms of type 3 Gaucher in adults, a decision that arrived in the US nearly 30 years after Europe approved the same use. That lag says something uncomfortable about how long rare disease patients in America sometimes wait for treatments already available elsewhere.
Sanofi also markets Cerdelga, an oral drug approved in 2014 for adults with type 1 Gaucher. Both Cerezyme and Cerdelga trace their roots to Genzyme, the biotech company Sanofi acquired in 2011. Together, the two products generated more than 1 billion euros, roughly $1.1 billion, in global sales during 2025. Infilbray, which also originated at Genzyme, now gives Sanofi a third product in its Gaucher portfolio, and the first one built to reach the brain.
Not every chapter of Infilbray's story has been a win. Last year, Sanofi reported that the drug failed to meet its goals in a Phase 3 trial for Fabry disease, another rare condition caused by an enzyme deficiency. That outcome is a useful reminder that a drug's success in one rare disease does not guarantee success in another, even when the underlying biology looks similar on paper.
For type 3 Gaucher, Infilbray remains under regulatory review in Europe and Japan, and Sanofi has said it plans additional regulatory submissions in other markets over the coming year. Patients and advocacy groups outside the United States will be watching those decisions closely, since access to this kind of targeted therapy can vary dramatically by country and by how quickly regulators act.
For the type 3 Gaucher community in the US, the approval marks a genuine turning point, even if it is not a cure. It does not undo damage already done to the nervous system, and the suicide risk warning demands careful monitoring rather than casual optimism. What it does offer is something families have waited a long time for: a therapy aimed directly at the part of the disease that enzyme replacement never could reach. For a condition that steals cognitive function and muscle control year after year, that targeted reach matters enormously, both as treatment and as proof that the blood-brain barrier is not an unbeatable wall for rare disease drug developers.
Tags
Original Sources
FDA Approval for Sanofi Drug Marks an Important First in Rare Disease - MedCity News
↗ https://medcitynews.com/2026/11/sanofi-gaucher-disease-type3-venglustat-infilbray-fda-approval-gd3-san
About the author
Amara's entry point into AI was an epidemiology role at a London research hospital, where she spent five years studying how digital health tools reached — or conspicuously failed to reach — underserved communities. Watching early algorithmic systems in healthcare quietly entrench existing inequalities, she redirected her career toward the systemic consequences of AI at scale. She covers AI through an unflinching lens: who benefits, who bears the cost, and what evidence actually says versus what the press release claims. Her writing is calm and precise, but she doesn't mistake balance for neutrality.
More from The Steward →This Week's Edition
20 November 2026
29 articles
Related Articles

Merck Taps Isomorphic Labs for AI-Designed Oncology Drug in Latest Pharma-AI Tie-Up
Health & Science · 5 min

Stanford Pairs AI With Brain Science to Tackle Depression, Memory, and How the Mind Develops
Health & Science · 6 min

National Academies Report Calls for Faster, Tougher Retraction Standards
Models & Research · 5 min
Related Articles

Merck Taps Isomorphic Labs for AI-Designed Oncology Drug in Latest Pharma-AI Tie-Up
Health & Science · 5 min

Stanford Pairs AI With Brain Science to Tackle Depression, Memory, and How the Mind Develops
Health & Science · 6 min

National Academies Report Calls for Faster, Tougher Retraction Standards
Models & Research · 5 min
More Stories
© 2026 Cedar & Bloom. All rights reserved.